Farmak International Reports 23 Product Launches in Q1 2026
23 launches across Europe, MEA, and SEA, representing 19 products in key therapeutic areas
In Q1 2026, Farmak International completed 23 product launches across 9 countries, expanding its portfolio across multiple therapeutic areas. These launches covered Europe, the Middle East and Africa (MEA), and Southeast Asia (SEA).
These results show Farmak International’s ongoing execution of its global strategy to build a balanced, scalable portfolio of complex generics. The diverse launches highlight the company’s ability to expand regionally while maintaining focus on hospital-based treatments and core expertise.
Focus on Key Therapeutic Areas
The Q1 launches focused on several core therapeutic segments:
▶ Ophthalmology – focusing on glaucoma, intraocular pressure control, and anti-inflammatory therapies
▶ Diagnostic imaging – including contrast agents used in MRI and CT procedures
▶ Anaesthesiology and intensive care products – with short-acting anesthetics and sedatives for hospital use
▶ Intensive care solutions – for managing critical conditions with hemodynamic support
▶ Cardiology products – for anticoagulation, antiplatelet activity, and chronic cardiovascular conditions
▶ Systemic hormonal therapies – addressing endocrine-related conditions
▶ Musculoskeletal system medicines – for pain and inflammation management
This distribution demonstrates ongoing portfolio development in ophthalmology, growth in diagnostic imaging, and a sustained focus on hospital- and critical-care medicines.
We are building a portfolio focused on complexity, critical care, and diagnostic capabilities. Our priority is not scale alone, but creating a sustainable platform for growth across key global markets
Pavlo Savenko Launch Management Director, Farmak International
Geographic Reach
Most launches occurred in the Middle East and Africa, followed by Europe, Southeast Asia, and key markets such as the United Kingdom.
The company remains dedicated to driving quality medicines worldwide and building long-term partnerships for better health outcomes and sustainable growth.
Product availability, regulatory status, and commercialization rights vary by country and may be restricted by intellectual property rights or other legal requirements. Products are not offered for sale or supplied where such rights prohibit sale or would result in intellectual property rights infringement. Customers are responsible for verifying all relevant intellectual property rights (including patents and SPCs) and for ensuring compliance with local laws.
Business inquiries:
bd@farmak.ch
Media inquiries:
media@farmak.ch
